Endonovo Therapeutics, Inc. SEC filings ENDV

Endonovo Therapeutics, Inc. has 502 filings in SEC EDGAR's recent list, going back to Sep 22, 2011. Its latest annual report, Form 10-K, was filed on Apr 17, 2023 for the period ended Dec 31, 2022. The latest quarterly report (Form 10-Q) was filed on Dec 29, 2023, covering the quarter ended Sep 30, 2023. The most recent current report (Form 8-K) was filed on Jan 3, 2024 (material agreement). The company's fiscal year ends on December 31.

Endonovo Therapeutics, Inc. SEC filings
Form Description Filed Period
DEF 14C Information statement Nov 14, 2019 Nov 14, 2019
DEF 14A Proxy statement Nov 14, 2019 Nov 13, 2019
PRE 14C Filing Oct 31, 2019 Oct 30, 2019
DEF 14C Information statement Aug 28, 2018 Aug 28, 2018
PRE 14C Filing Aug 14, 2018 Aug 14, 2018
DEF 14C Information statement Dec 19, 2016 Dec 19, 2016
PRE 14C Filing Dec 8, 2016 Dec 8, 2016

Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
ENDV (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Woodland Hills, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1528172
Former names
Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.